Cited 24 times in
Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형우 | - |
dc.contributor.author | 박정탁 | - |
dc.contributor.author | 유태현 | - |
dc.contributor.author | 윤해룡 | - |
dc.contributor.author | 주영수 | - |
dc.contributor.author | 한승혁 | - |
dc.contributor.author | 강신욱 | - |
dc.date.accessioned | 2022-12-22T02:57:54Z | - |
dc.date.available | 2022-12-22T02:57:54Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1046-6673 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191752 | - |
dc.description.abstract | Background: An elevated coronary artery calcification score (CACS) is associated with increased cardiovascular disease risk in patients with CKD. However, the relationship between CACS and CKD progression has not been elucidated. Methods: We studied 1936 participants with CKD (stages G1-G5 without kidney replacement therapy) enrolled in the KoreaN Cohort Study for Outcome in Patients With CKD. The main predictor was Agatston CACS categories at baseline (0 AU, 1-100 AU, and >100 AU). The primary outcome was CKD progression, defined as a ≥50% decline in eGFR or the onset of kidney failure with replacement therapy. Results: During 8130 person-years of follow-up, the primary outcome occurred in 584 (30.2%) patients. In the adjusted cause-specific hazard model, CACS of 1-100 AU (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.04 to 1.61) and CACS >100 AU (HR, 1.42; 95% CI, 1.10 to 1.82) were associated with a significantly higher risk of the primary outcome. The HR associated with per 1-SD log of CACS was 1.13 (95% CI, 1.03 to 1.24). When nonfatal cardiovascular events were treated as a time-varying covariate, CACS of 1-100 AU (HR, 1.31; 95% CI, 1.07 to 1.60) and CACS >100 AU (HR, 1.46; 95% CI, 1.16 to 1.85) were also associated with a higher risk of CKD progression. The association was stronger in older patients, in those with type 2 diabetes, and in those not using antiplatelet drugs. Furthermore, patients with higher CACS had a significantly larger eGFR decline rate. Conclusion: Our findings suggest that a high CACS is associated with significantly increased risk of adverse kidney outcomes and CKD progression. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Nephrology | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Coronary Artery Disease / complications* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2 / complications* | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Renal Insufficiency, Chronic / complications | - |
dc.subject.MESH | Renal Insufficiency, Chronic / etiology* | - |
dc.subject.MESH | Renal Insufficiency, Chronic / therapy | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Vascular Calcification / complications* | - |
dc.subject.MESH | Vascular Calcification / etiology | - |
dc.title | Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hae-Ryong Yun | - |
dc.contributor.googleauthor | Young Su Joo | - |
dc.contributor.googleauthor | Hyung Woo Kim | - |
dc.contributor.googleauthor | Jung Tak Park | - |
dc.contributor.googleauthor | Tae Ik Chang | - |
dc.contributor.googleauthor | Nak-Hoon Son | - |
dc.contributor.googleauthor | Tae-Hyun Yoo | - |
dc.contributor.googleauthor | Shin-Wook Kang | - |
dc.contributor.googleauthor | Suah Sung | - |
dc.contributor.googleauthor | Kyu-Beck Lee | - |
dc.contributor.googleauthor | Joongyub Lee | - |
dc.contributor.googleauthor | Kook-Hwan Oh | - |
dc.contributor.googleauthor | Seung Hyeok Han | - |
dc.identifier.doi | 10.1681/ASN.2022010080 | - |
dc.contributor.localId | A01151 | - |
dc.contributor.localId | A01654 | - |
dc.contributor.localId | A02526 | - |
dc.contributor.localId | A04617 | - |
dc.contributor.localId | A03956 | - |
dc.contributor.localId | A04304 | - |
dc.contributor.localId | A00053 | - |
dc.relation.journalcode | J01779 | - |
dc.identifier.eissn | 1533-3450 | - |
dc.identifier.pmid | 35654602 | - |
dc.identifier.url | https://jasn.asnjournals.org/content/33/8/1590.long | - |
dc.subject.keyword | chronic renal disease | - |
dc.subject.keyword | clinical nephrology | - |
dc.subject.keyword | coronary artery disease | - |
dc.subject.keyword | coronary calcification | - |
dc.subject.keyword | vascular calcification | - |
dc.contributor.alternativeName | Kim, Hyung Woo | - |
dc.contributor.affiliatedAuthor | 김형우 | - |
dc.contributor.affiliatedAuthor | 박정탁 | - |
dc.contributor.affiliatedAuthor | 유태현 | - |
dc.contributor.affiliatedAuthor | 윤해룡 | - |
dc.contributor.affiliatedAuthor | 주영수 | - |
dc.contributor.affiliatedAuthor | 한승혁 | - |
dc.contributor.affiliatedAuthor | 강신욱 | - |
dc.citation.volume | 33 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1590 | - |
dc.citation.endPage | 1601 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, Vol.33(8) : 1590-1601, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.